FDA approves new mechanism to treat idiopathic pulmonary fibrosis, expanding limited arsenal - Nature Biotechnology The first-in-class small molecule Jascayd targets a fibrotic signaling cascade, offering new hope in a stagnant therapeutic field, as several other programs near maturity.

The first-in-class small molecule #Jascayd targets a fibrotic signaling cascade, offering new hope in a stagnant therapeutic field, as several other programs near maturity www.nature.com/articles/s41...

💊 FDA Approval Update | #FDA approves #Jascayd (#nerandomilast) for idiopathic pulmonary fibrosis — first new #IPF drug in 10+ years.
✅ Smaller #FVC decline vs placebo
✅ 18 mg twice daily
Read more: https://ow.ly/8z7b50X93Ea
#PulmonaryFibrosis